Solventum Corporation (NYSE:SOLV) Given Average Rating of "Hold" by Analysts

Key Points

• Analyst consensus: Thirteen brokerages give Solventum an average "Hold" rating (7 Buy, 5 Hold, 1 Sell) with a 1‑year average price target of $89.45.
• Q4 results & guidance: The company beat estimates with $1.57 EPS (vs. $1.50) and $2.0B revenue, though revenue was down 3.7% year‑over‑year; management set FY2026 EPS guidance of $6.40–$6.60 (analysts ~6.5).
• Stock and valuation: SOLV traded near $66.49 with a 52‑week range of $62.38–$88.20, a market cap of ~$11.5B and a P/E of 7.5, indicating a relatively low valuation despite mixed top‑line trends.

Shares of Solventum Corporation (NYSE:SOLV - Get Free Report) have been assigned an average rating of "Hold" from the thirteen brokerages that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $89.4545.

SOLV has been the subject of several research reports. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Solventum in a research report on Tuesday, January 27th. Rothschild & Co Redburn initiated coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a "sell" rating and a $60.00 price target for the company. BTIG Research reiterated a "buy" rating and set a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Mizuho set a $100.00 price objective on Solventum and gave the company an "outperform" rating in a research note on Tuesday, January 20th. Finally, Wells Fargo & Company upgraded Solventum to a "hold" rating in a research note on Wednesday, March 18th.

Solventum Price Performance

NYSE SOLV opened at $66.49 on Thursday. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The firm has a market capitalization of $11.53 billion, a P/E ratio of 7.50, a PEG ratio of 1.14 and a beta of 0.71. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00. The company has a 50-day moving average price of $68.11 and a 200-day moving average price of $74.53.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported $1.57 EPS for the quarter, beating the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same quarter in the prior year, the firm earned $1.41 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Equities research analysts anticipate that Solventum will post 6.5 earnings per share for the current year.

Insider Activity

In related news, Director Amy Mcbride Wendell acquired 1,475 shares of the business's stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the purchase, the director owned 5,039 shares in the company, valued at $342,803.17. The trade was a 41.39% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.24% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Hilltop National Bank grew its stake in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company's stock valued at $25,000 after acquiring an additional 129 shares during the period. CrossGen Wealth LLC bought a new position in shares of Solventum during the 4th quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC bought a new position in shares of Solventum during the 3rd quarter valued at approximately $25,000. JNBA Financial Advisors grew its stake in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company's stock valued at $27,000 after acquiring an additional 228 shares during the period. Finally, CYBER HORNET ETFs LLC bought a new position in shares of Solventum during the 2nd quarter valued at approximately $28,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.